NSAIDs: More Bad News
NSAIDs are an $11-12+ billion market, yet the problems with these drugs continue to make headlines. The most recent study examined data from nearly 450,000 patients, and concluded (our…
Menu
Drug Overdose Deaths: What Can Pharma Do?
Last week, the US Centers for Disease Control published a rather alarming report on drug overdose deaths in the US. Here are a few items which we found…
Looking Backward, Looking Forward
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
Some Comments On Marijuana
The recent elections in the United States is bringing many long-standing policies into question. And, the continued legalization of marijuana is one of them. At Lacerta Bio, we have consistently…
The $25 Coffee Mug
Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again). One presentation at NLSD by SwedenBio enlightened us on how…
The Age of Virtual Pharma: Creative Financing and Exit Models
At last month's Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It…
Would Mefloquine Be Approved Today?
As part of my preparations for an upcoming trip to India, my physician prescribed a 6-week prophylactic course of mefloquine to prevent malaria. The weekly dosing schedule prompted me to…
Adaptive Licensing: An Idea Ready For Prime Time?
We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward…
Employee-Free Biotechs: A Virtual Panacea?
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
On Failure
These past few weeks I have noticed how negative and bimodal we have become when clinical results are announced. More and more, Phase II and III results are labeled #FAIL…